Ameritas Advisory Services LLC Invests $84,000 in DexCom, Inc. $DXCM

Ameritas Advisory Services LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 966 shares of the medical device company’s stock, valued at approximately $84,000.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC grew its stake in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in DexCom by 29.3% in the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company’s stock valued at $209,000 after acquiring an additional 702 shares during the last quarter. SG Americas Securities LLC lifted its stake in DexCom by 193.6% in the first quarter. SG Americas Securities LLC now owns 17,097 shares of the medical device company’s stock valued at $1,168,000 after acquiring an additional 11,273 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of DexCom by 0.6% in the first quarter. Assenagon Asset Management S.A. now owns 650,679 shares of the medical device company’s stock valued at $44,435,000 after purchasing an additional 3,833 shares during the period. Finally, Fifth Third Bancorp increased its position in DexCom by 1.0% during the first quarter. Fifth Third Bancorp now owns 31,656 shares of the medical device company’s stock worth $2,162,000 after acquiring an additional 309 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on DXCM shares. UBS Group boosted their target price on shares of DexCom from $105.00 to $106.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Citigroup reduced their price target on shares of DexCom from $105.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday. Truist Financial began coverage on shares of DexCom in a research report on Monday, June 16th. They set a “buy” rating and a $102.00 target price on the stock. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. Finally, Mizuho increased their target price on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 16th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $97.42.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 500 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president owned 94,102 shares of the company’s stock, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kyle Malady sold 667 shares of the stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director directly owned 22,667 shares of the company’s stock, valued at $1,832,853.62. This represents a 2.86% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,849 shares of company stock worth $564,733 in the last 90 days. Corporate insiders own 0.32% of the company’s stock.

DexCom Stock Down 4.3%

DXCM stock opened at $65.12 on Friday. The company has a market cap of $25.54 billion, a PE ratio of 45.22, a price-to-earnings-growth ratio of 1.43 and a beta of 1.47. The business has a 50-day simple moving average of $74.42 and a 200 day simple moving average of $77.62. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.DexCom’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.